Nextech

Finding and fueling tomorrow’s advances in precision medicine.

[Context Therapeutics @Context_Tx]

Today, we announced a $100 million private placement. This financing, together with Context's existing cash and cash equivalents, is expected to extend our cash runway into 2028. $CNTX https://t.co/jxDLb8vplZ

[Thilo Schroeder @schroederthilo]

$RVMD and $EQRX merge to build a Ras powerhouse.
https://t.co/oRHiSiecDL

[Nextech @NextechInvest]

https://t.co/lPnZlyidWx

[Thilo Schroeder @schroederthilo]

Congrats @oricpharma
and @JacobChackoMD on closing this PIPE. It also marks @NextechInvest first PIPE investment. We are excited about working together with this very talented team to advance the high potential pipeline
https://t.co/92qhSeS3Bl

[Fred Hutch Cancer Center @fredhutch]

Congratulations to Fred Hutch's Dr. Phil Greenberg on his election to @theNASciences! Greenberg is an internationally-recognized expert in cancer #immunotherapy, a form of therapy that aims to harness the power of immune cells to eliminate #cancer. https://t.co/fsKPbI6cI7

[Nextech @NextechInvest]

Thank you @Nasdaq for highlighting our recent financing of Alpha-9. Great team, science and syndicate!

[The Nobel Prize @NobelPrize]

"I think success is having a career where you enjoy it so much that you almost feel guilty that people pay you to do it because you are having so much fun every day."

Wise words by our 2019 medicine laureate William Kaelin.

#NobelPrize

[Lowe Lab @LoweLabMSKCC]

Farewell to our latest graduate, Dr. @StellaPaff, and best of luck for her next endeavor @NextechInvest! #LoweLab25

[Kauffman Fellows @KauffmanFellows]

So grateful for the incredible LPs who joined our healthcare SIG this afternoon and shared how venture firms can create value, promote ongoing engagement, and prioritize LP's unique motivations. Shout out to our moderator, Melisa McCracken of @NextechInvest 👋🏽🔥

[STAT @statnews]

IDRx is starting off with $122 million and two licensed drug candidates it plans to combine to create a treatment for gastrointestinal stromal tumors, or GIST. https://t.co/XMxwdfSMpD

[The Boston Globe @BostonGlobe]

Startup IDRx raises $122m to focus on combination drug treatments https://t.co/2XLfJWEbSu

[Jorge Conde @JorgeCondeBio]

IDRx is launching w/ $122m to treat cancer with ‘purpose-built’ precision combination therapies.

@a16z is thrilled to co-lead this financing w/ @cascapital + participation from @NextechInvest, Forge Life Science Partners & other investors.

https://t.co/tVcjehLLMD

[Arrakis Therapeutics @ArrakisTx]

At Arrakis, we have a simple but powerful vision: To extend medicines into new realms of biology by discovering and developing rSMs (RNA-targeted small molecules) that act directly on RNA to treat disease. Happy #RNADay!

[pmvpharma @pmvpharma]

We are thrilled to announce our collaboration with Merck to evaluate PC14586 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors.

https://t.co/OfPXA2hyYH

#p53 #oncology

[Ambagon Therapeutics @ambagontx]

Please join us in congratulating our Co-Founder, Luc Brunsveld, on his election to the Royal Dutch Academy of Sciences. Beyond his work as a professor at @TUeindhoven, Luc’s leadership and scientific contributions to the Ambagon team are appreciated and celebrated every day.

[Ambagon Therapeutics @ambagontx]

This week our CSO, @NanPry, is at the second Annual Induced Proximity-Based Drug Discovery Summit in Boston to share the latest on Ambagon’s work developing a modular approach to drug discovery. Nancy will speak on Thursday, May 12.

More on this event: https://t.co/3h7uZv0vMd

[MOMA Therapeutics @moma_tx]

We're excited to announce the completion of our Series B financing, advancing our novel #drugdiscovery platform to develop precision medicines for patients in need. Read more here: https://t.co/I5GLbND81B

[Thilo Schroeder @schroederthilo]

Fueling the motors!
Great sign of life in this market. Strong science will always get funded. We believe in #biotech. We'll done @moma_tx and great to work with a strong syndicate of @ThirdRockV, Cormorant, @section32vc, @NextechInvest and the new lead @GoldmanSachs

[C4 Therapeutics @C4Therapeutics]

Today we announced clinical data from our ongoing Phase 1/2 clinical trial of CFT7455 for the treatment of multiple myeloma and non-Hodgkin’s lymphomas, to be presented at #AACR22. Read more in our news release: https://t.co/oGdx6qipn2